In this episode, we break down the complex pathophysiological and genetic landscape of acromegaly, looking beyond the simple diagnosis of growth hormone hypersecretion. We explore the critical cellular differences between densely and sparsely granulated somatotroph adenomas, detailing how their unique cytokeratin networks and somatostatin receptor profiles dictate treatment response. Finally, we examine the genetic drivers behind familial syndromes like Carney complex and X-linked acrogigantism, alongside the diagnostic challenges posed by rare ectopic tumors.

This episode delivers a comprehensive clinical review of metabolic dysfunction associated steatotic liver disease (MASLD) and its progressive stage, metabolic dysfunction associated steatohepatitis (MASH). We explore the multi organ pathogenic cascade driven by insulin resistance and lipotoxicity. Listeners will gain practical insights into non invasive risk stratification using the FIB-4 index and transient elastography, alongside evidence based management strategies spanning targeted pharmacotherapies like resmetirom, incretin mimetics, and structured lifestyle modifications.

In this episode, we unpack the complex mechanisms of Thyroid Eye Disease (TED). Explore the synergistic crosstalk between TSH and IGF-1 receptors on orbital fibroblasts, driving adipogenesis and fibrosis via hyaluronan accumulation. We break down the clinical activity score, staging protocols, and first-line therapies—including intravenous methylprednisolone regimens and the targeted IGF-1 receptor antagonist teprotumumab. Finally, we outline the strict sequential surgical management required for stable, inactive disease.

This episode explores the critical transition from uncomplicated thyrotoxicosis to thyroid storm, focusing on the systemic homeostatic collapse driven by cellular hyper-responsiveness rather than absolute serum hormone concentrations. We analyze the molecular mechanisms of hyperpyrexia via mitochondrial uncoupling proteins one and three, alongside the intracellular signaling changes that cause profound hyper-adrenergic hypersensitivity despite normal catecholamine levels. The discussion details the progression from a high-output hyperkinetic cardiac state to low-output cardiogenic shock, the development of perivenular hepatic necrosis, and the neuro-excitatory pathways leading to central nervous system decline, equipping clinicians to recognize the physiological triggers of this endocrine emergency.

This episode reviews the clinical pharmacology of propylthiouracil and its evolution in modern endocrinology practice. We examine its history from its discovery in the 1940s to its replacement by methimazole as the preferred first-line antithyroid therapy. The discussion covers the unique dual mechanism of propylthiouracil, focusing on both thyroid peroxidase inhibition and the inhibition of peripheral conversion of thyroxine to triiodothyronine via type one deiodinase. We analyze the essential clinical exceptions where propylthiouracil remains mandatory, specifically thyroid storm and first-trimester pregnancy management. Finally, we address serious toxicity profiles including severe hepatotoxicity, agranulocytosis, and antineutrophil cytoplasmic antibody associated vasculitis.

This episode provides a comprehensive review of methimazole for clinical endocrinologists, focusing on its historical context, pharmacological profile, and practical management strategies. We examine its mechanism of action, specifically the inhibition of thyroid peroxidase to block iodine organification and coupling, alongside its distinct pharmacokinetics that allow for once-daily dosing. The discussion covers precise titration strategies for mild to severe hyperthyroidism, monitoring protocols using thyroid function tests, and methods for tapering. Finally, we analyze the drug safety profile, differentiating minor cutaneous reactions from major idiosyncratic toxicities like agranulocytosis and cholestatic hepatotoxicity, while addressing first-trimester teratogenicity risks and pregnancy transitions.

This podcast episode provides an advanced clinical review of maternal thyroid dysfunction during gestation and the postpartum period tailored for practicing endocrinologists. The discussion analyzes the physiological stress test of pregnancy on maternal thyroid kinetics including the role of human chorionic gonadotropin and altered iodine clearance. Listeners will review the transition away from rigid trimester cutoffs to population based reference ranges alongside the challenges of standard free thyroxine immunoassays. The episode outlines precise levothyroxine titration protocols for overt and subclinical hypothyroidism stratified by antibody status and details the critical first trimester selection of propylthiouracil over methimazole to mitigate embryopathy risks. Finally the presentation covers the management of postpartum thyroiditis and the latest targeted case finding strategies for high risk patients.

This podcast episode covers the clinical landscape of immune checkpoint inhibitor induced endocrinopathies, focusing on mechanisms, diagnostic pathways, and long-term management strategies for practicing endocrinologists. Listeners will review the presentation of anti-CTLA-four induced hypophysitis, including its classic biphasic manifestation of pituitary swelling followed by central axes deficiencies. The episode contrasts this with the destructive, painless thyroiditis typically triggered by anti-PD-one and anti-PD-L-one agents, detailing the hyperacute shift from transient thyrotoxicosis to permanent hypothyroidism. Finally, the discussion addresses rapid beta-cell destruction leading to fulminant insulin-dependent diabetes, alongside rare toxicities like primary adrenalitis and hypoparathyroidism, emphasizing mandatory pre-cycle surveillance protocols.

This episode provides a high-level review of metformin, tracing its evolution from French lilac to the cornerstone of metabolic medicine. We explore its dual molecular mechanisms, balancing canonical AMPK-dependent pathways with non-canonical actions like mGPD inhibition and gut-brain axis modulation. The discussion reviews core clinical evidence from the UKPDS and DPP trials, examines its role in treating tissue-specific insulin resistance in polycystic ovary syndrome, and analyzes emerging data regarding mTOR inhibition in long COVID. Finally, we break down the pathophysiology of gastrointestinal distress, vitamin B12 deficiency, and the strict eGFR-based parameters required to mitigate the risk of lactic acidosis.

This episode reviews primary aldosteronism management, focusing on universal screening mandates and optimized pre analytic protocols to prevent false results. We break down the diagnostic workup, comparing immunoassay and mass spectrometry cutoffs, and discuss when to bypass confirmatory testing for direct lateralization. The discussion covers subtype classification using computed tomography and adrenal venous sampling, including exceptions for select young patients. Finally, we review therapeutic strategies, detailing unilateral laparoscopic adrenalectomy for lateralized disease and medical management with mineralocorticoid receptor antagonists, emphasizing the clinical importance of titrating medication doses to unmask suppressed renin levels and mitigate adverse long term cardiovascular tissue damage.